Results 171 to 180 of about 10,401 (200)

Mepolizumab in Chronic Obstructive Pulmonary Disease (COPD): A new frontier in biologic therapy. [PDF]

Saudi J Anaesth
Mukesh A, Chittoria K, Sharma A.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Mepolizumab

Reactions Weekly, 2022
  +10 more sources

Mepolizumab

Reactions Weekly, 2023
  +5 more sources

Mepolizumab

Reactions Weekly, 2019
  +9 more sources

Mepolizumab

Reactions Weekly, 2018
  +7 more sources

Mepolizumab

Reactions Weekly, 2021
  +5 more sources

Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial

Lancet Respiratory Medicine,the, 2021
Claus Bachert, Wytske J Fokkens, Martin Desrosiers   +2 more
exaly  

Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational Study

Arthritis and Rheumatology, 2022
Alessandra Bettiol, Maria Letizia Urban, Lorenzo Dagna   +2 more
exaly  

The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational study

Lancet Respiratory Medicine,the, 2021
P Jane Mcdowell, John Busby, Rahul Shrimanker   +2 more
exaly